

## Chapter 5

# Approach to Psychogenic Coma in the ICU



### 5.1 Introduction

Psychogenic coma is a condition where a patient appears to be in a comatose state without an identifiable organic cause. This presentation is often linked to psychiatric disorders and can pose significant diagnostic and therapeutic challenges. Effective management requires a structured approach to ensure patient safety, accurate diagnosis, and appropriate treatment. The following write-up details the step-by-step management strategy as outlined in the flowchart, providing comprehensive explanations for each step and decision point [1, 2]. (Ref. Algorithm 5.1).

#### 5.1.1 *Establish a Safe Environment*

**Rationale:** The primary step in managing any patient in a comatose state is to ensure their environment is safe. This includes removing any potential hazards that could cause harm to the patient or healthcare providers.

**Considerations:** Ensure that the patient is in a calm, secure setting, possibly with restraints if they pose a danger to themselves or others.

#### 5.1.2 *Monitor Vital Signs and Neurological Reassessment*

**Rationale:** Continuous monitoring of vital signs (heart rate, blood pressure, respiratory rate, and oxygen saturation) is crucial to detect any changes in the patient's physiological status. Regular neurological reassessment helps in tracking any changes in the patient's neurological function.

Considerations: Utilize tools like the Glasgow Coma Scale (GCS) to systematically assess the patient's level of consciousness. Frequent checks are essential to identify any deterioration that may indicate an organic cause.

### ***5.1.3 Psychiatric Evaluation***

Rationale: A thorough psychiatric evaluation is necessary to identify any underlying psychiatric conditions that may contribute to the psychogenic coma. Neurological reassessment continues to ensure no new neurological findings are missed.

Considerations: Engage a psychiatrist early in the evaluation process. Utilize structured interviews and standardized tools to assess the patient's mental state.

### ***5.1.4 Amytal Interview***

The Amytal interview, also known as a “sodium Amytal interview” or “truth serum interview,” is a diagnostic and therapeutic procedure used primarily in psychiatry and neurology. Sodium Amytal, a barbiturate, is administered intravenously to induce a state of reduced inhibition, relaxation, and mild sedation. This altered state can facilitate communication and uncover psychological conditions that may not be apparent in a fully conscious state [3, 4]. Here is a detailed description of the Amytal interview process:

### ***5.1.5 Purpose and Indications***

The Amytal interview is employed to:

- Differentiate between organic and psychogenic disorders.
- Elicit hidden or repressed information.
- Aid in the diagnosis of conditions such as conversion disorder, catatonia, and psychogenic seizures.
- Provide therapeutic insight into unconscious conflicts and psychological issues.

### ***5.1.6 Procedure***

#### **1. Preparation**

- **Patient Consent:** Obtain informed consent from the patient, explaining the purpose, potential benefits, and risks of the procedure.

- **Environment:** Conduct the interview in a quiet, controlled setting, typically with a psychiatrist or neurologist present. Monitoring equipment should be available to track vital signs.

## 2. Administration

- **Intravenous Injection:** Sodium Amytal is administered intravenously, typically at a dose of 250–500 mg, titrated to effect. The onset of action is usually within a few minutes.
- **Monitoring:** Continuous monitoring of the patient's vital signs, including heart rate, blood pressure, and oxygen saturation, is essential throughout the procedure.

## 3. Interview Process

- **Induction Phase:** As the drug takes effect, the patient enters a state of reduced inhibition and relaxation. The clinician observes for signs of relaxation and responsiveness.
- **Questioning:** The clinician asks open-ended and specific questions to explore the patient's mental state, emotional conflicts, and responses to stimuli. The questions should be gentle and nonconfrontational to encourage the patient to speak freely.
- **Observation:** The clinician carefully notes the patient's responses, emotional reactions, and any emergence of repressed or hidden information.

## 4. Post-Interview

- **Recovery:** After the interview, the patient is monitored until the effects of the drug wear off. This typically takes about 30–60 minutes.
- **Debriefing:** The clinician discusses the findings with the patient once they are fully alert, providing insight and therapeutic guidance based on the information obtained.

### 5.1.7 Benefits

- **Diagnostic Clarity:** Helps distinguish between psychogenic and organic causes of symptoms.
- **Therapeutic Insight:** Uncovers repressed conflicts and emotions, aiding in therapeutic planning.
- **Enhanced Communication:** Facilitates communication in patients who may be nonresponsive or uncooperative in a fully conscious state.

### **5.1.8 Risks and Considerations**

- **Side Effects:** Possible side effects include drowsiness, dizziness, nausea, and respiratory depression.
- **Contraindications:** Not recommended for patients with a history of severe respiratory conditions, barbiturate allergy, or certain psychiatric disorders.
- **Ethical Concerns:** The use of Amytal interviews should be ethically justified, with a clear clinical indication and patient consent.

## **5.2 Types of Psychogenic Coma**

### **5.2.1 Conversion Reaction**

**Psychotherapy:** Engaging the patient in psychotherapy helps address the underlying psychological issues.

**Cognitive-Behavioral Therapy (CBT):** CBT is effective in modifying dysfunctional thoughts and behaviors.

**Stress Management:** Techniques for managing stress are crucial in preventing recurrence.

**Catatonia.**

**Benzodiazepines:** Medications like lorazepam are commonly used to treat catatonia.

**Electroconvulsive Therapy (ECT):** ECT is effective for patients not responding to benzodiazepines, particularly in severe cases.

### **5.2.2 Psychogenic Seizures**

**Education:** Informing the patient and their family about the nature of psychogenic seizures is vital.

**Psychotherapy:** Therapy helps address the psychological triggers.

**Avoiding Antiepileptic Drugs:** Since these seizures are not epileptic in origin, anti-epileptic drugs are generally not indicated.

### ***5.2.3 Cerebellar Cognitive Affective Syndrome***

Neuropsychological Rehabilitation: Tailored rehabilitation programs help improve cognitive and affective functions.

Supportive Therapy: Providing emotional and psychological support is crucial for recovery.

### ***5.2.4 Reevaluate for Potential Organic Causes***

If all evaluations and interventions indicate no psychogenic cause, reevaluation for potential organic causes is conducted using:

EEG: Electroencephalogram helps in identifying any underlying epileptic activity.


MRI: Magnetic resonance imaging can detect structural brain abnormalities that might contribute to the coma.

- By following this structured approach, clinicians can systematically identify and address the underlying causes of psychogenic coma, ensuring comprehensive and effective patient care.

## **5.3 Conclusion**

Managing psychogenic coma requires a multidisciplinary approach involving careful assessment, monitoring, and intervention. Establishing a safe environment, continuous monitoring, thorough psychiatric and neurological evaluations, and the use of an Amytal interview are crucial steps. Treatment varies based on the specific diagnosis, with psychotherapy, pharmacotherapy, and supportive therapies playing key roles. Reevaluation is necessary if initial tests suggest no psychogenic cause.

Algorithm 5.1: Approach to psychogenic coma in the ICU



Bibliography

1. Ryznar E, Wilcox D. Functional coma: two case reports and a review of the literature. Psychosomatics. 2019;60(4):343–51.
2. Kim SH, Kim KM, Lim YH, Yoo BH, Cho J, Jun IJ. Psychogenic coma after general anesthesia with remimazolam and remifentanyl -a case report. Korean J Anesthesiol. 2022;75(5):449–52.
3. Naples M, Hackett TP. The amytal interview: history and current uses. Psychosomatics. 1978;19(2):98–105.
4. Perry JC, Jacobs D. Overview: clinical applications of the amytal interview in psychiatric emergency settings. Am J Psychiatry. 1982;139(5):552–9.